Vifor Pharma AG Logo

Vifor Pharma AG

A global leader in specialty pharmaceuticals for iron deficiency and nephrology.

VIFN | SW

Overview

Corporate Details

ISIN(s):
CH0364749348
LEI:
529900KO6CN2D9OE1F19
Country:
Switzerland
Address:
Rechenstrasse 37, 9014 St. Gallen
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

CSL Vifor is a global specialty pharmaceuticals company and a leader in iron deficiency and nephrology therapies. As a pioneer in iron-based treatments, the company develops, manufactures, and markets innovative products for iron deficiency anemia and related conditions in areas including heart failure, gastroenterology, and women's health. In partnership with its joint company, Vifor Fresenius Medical Care Renal Pharma, CSL Vifor is expanding its presence in nephrology, committed to launching therapies that address the full spectrum of kidney disease. The company specializes in strategic global partnering, in-licensing, and marketing pharmaceutical products to serve patients with unmet medical needs in over 100 countries.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Vifor Pharma AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Vifor Pharma AG

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Vifor Pharma AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2022-03-09 N/A Executive member Sell None 4,335,210.00 CHF
2022-03-09 N/A Non-Executive member Sell None 1,951,125.00 CHF
2022-03-09 N/A Non-Executive member Sell None 1,851,300.00 CHF
2022-03-09 N/A Executive member Sell None 1,535,160.00 CHF
2022-03-09 N/A Non-Executive member Sell None 1,450,515.00 CHF
2022-03-09 N/A Executive member Sell None 920,205.00 CHF
2022-03-09 N/A Executive member Sell None 530,310.00 CHF
2022-03-09 N/A Non-Executive member Sell None 382,140.00 CHF
2022-03-09 N/A Non-Executive member Sell None 330,495.00 CHF
2022-03-09 N/A Executive member Sell None 287,925.00 CHF

Peer Companies

Company Country Ticker View
Kringle Pharma,Inc. Logo
Develops regenerative HGF medicines for rare and intractable neurological diseases.
Japan 4884
Krka Logo
Develops and sells generic prescription, non-prescription, and animal health products globally.
Slovenia KRKG
KUKJEON PHARMACEUTICAL Co.,Ltd Logo
A chemical solutions provider manufacturing Active Pharmaceutical Ingredients and electronic materials.
South Korea 307750
KWANGDONG PHARMACEUTICAL CO.,LTD Logo
Developing drugs & health goods by integrating oriental and Western medicine.
South Korea 009290
Kyivmedpreparat Logo
A leading pharmaceutical producer of antibacterial, generic, and original medicines in various forms.
Ukraine KMED
KYONGBO PHARMACEUTICAL CO., LTD. Logo
Manufactures APIs and finished drugs, offering global CDMO services from development to production.
South Korea 214390
KYORIN Pharmaceutical Co., Ltd. Logo
Researches, develops, and sells a portfolio of ethical, generic, and OTC medicines.
Japan 4569
Kyowa Kirin Co.,Ltd. Logo
Develops antibody medicines for oncology, nephrology, immunology, and allergy.
Japan 4151
KyungdongPharm Logo
Develops and manufactures Rx/OTC drugs & APIs for cardiology and other chronic conditions.
South Korea 011040
KYUNG NAM PHARM.CO.,LTD. Logo
South Korean maker of OTC medicines, health foods, and cosmetics, known for its Lemona Vitamin C.
South Korea 053950

Talk to a Data Expert

Have a question? We'll get back to you promptly.